Remote Supervision to Decrease Hospitalization Rate

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

600 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-09-30

Study Completion Date

2017-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Purpose: Home monitoring (HM) services supplied by different manufacturers (St Jude Medical, Biotronik, Medtronic) enables trained medical staff (doctors, electrophysiology nurses and technicians) to safely follow-up patients with implanted ICD/CRT-D remotely, with omitting unnecessary visits in outpatient clinic, shortening time to medical intervention and therefore help to decrease hospitalization rate among those patients.

The RESULT study primary endpoint of the trial will be a composite of all-cause death or hospitalization due to cardiovascular reasons.

The primary technical endpoint is to construct and evaluate a unified and integrated platform for data collected from RM devices manufactured by different companies: Carelink™ (Medtronic®, Minneapolis, MN, USA), Merlin™ (Saint Jude Medical®, St. Paul, MN, USA) and Home Monitoring™ (Biotronik®, Berlin, Germany).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Benefits of Implantable Cardioverter Defibrillator Follow-up Using Remote Monitoring

NCT00989417

Implantable Cardioverter-Defibrillators Ventricular Fibrillation Tachycardia, Ventricular

COMPLETED NA

INvestigation on Routine Follow-up in CONgestive HearT FAilure Patients With Remotely Monitored Implanted Cardioverter Defibrillators (ICD) SysTems

NCT01200381

Heart Failure

COMPLETED NA

Treatment Satisfaction in Implantable Cardioverter Defibrillator Recipients

NCT01230073

Improvement of Treatment Satisfaction

COMPLETED PHASE4

Home Monitoring in Cardiac Resynchronisation Therapy

NCT00376116

Heart Failure, Congestive

COMPLETED

Influence of Home Monitoring on the Clinical Status of Heart Failure Patients With an Impaired Left Ventricular Function

NCT00538356

Ventricular Fibrillation Ventricular Tachycardia Congestive Heart Failure

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The RESULT trial is a prospective, single-center, randomized, open label, parallel study. All consecutive patients with symptomatic HF and reduced ejection fraction (≤ 35%) with ICDs or CRT-Ds implanted accordingly to current ESC practice guidelines will be prospectively randomized in a 1:1 fashion to either a traditional or an RM-based follow-up model. Six hundred patients will be enrolled. The inclusion and exclusion criteria are shown in Table 1. The clinical status of patients will be estimated using the composite endpoint of all-cause death and hospitalization due to cardiovascular reasons. The study protocol has been approved by a local ethics committee and complies with the Declaration of Helsinki. A written informed consent will be obtained from all study participants. Primary endpoint The primary endpoint of the trial will be a composite of all-cause death or hospitalization due to cardiovascular reasons. Hospitalization for cardiovascular reasons should consist of:

* Hospitalization due to progression of heart failure.
* Hospitalization due to persistent arrhythmia (AF, VT).
* Hospitalization due to embolic episode.
* Hospitalization due to acute coronary syndrome. Every patient will be followed for at least 12 months after randomization. Assessment of hospitalization events for cardiovascular reasons will be performed according to a recently published consensus \[13\]. The final classification of hospital admissions due to cardiovascular reasons will be made by a blinded endpoints committee. The primary technical endpoint is to construct and evaluate a unified and integrated platform for data collected from RM devices manufactured by different companies: Carelink™ (Medtronic®, Minneapolis, MN, USA), Merlin™ (Saint Jude Medical®, St. Paul, MN, USA) and Home Monitoring™ (Biotronik®, Berlin, Germany). Secondary endpoints Both elements combined in the primary endpoint will be analyzed separately to estimate their relative impact on the primary endpoint.

The secondary endpoints include the following:

* All-cause death.
* Hospitalization due to cardiovascular reasons.
* Time to medical intervention in case of relevant incidents (arrhythmic, device malfunction, signs of HF decompensation).
* Average number of visits to an outpatient clinic (scheduled and unscheduled) per patient.
* Time to first unscheduled visit in an outpatient clinic.
* Incidence of inappropriate ICD shocks.
* Proportion of visits to outpatient clinics with relevant findings (necessity of changes of device programming or pharmacological therapy, rehospitalization, interventions, invasive procedures).
* Assessment of quality of life of living study participants according to the Minnesota Quality of Life Questionnaire.
* Cost-effectiveness, defined as the cost of hospitalizations and/or scheduled and unscheduled visits in both groups.

All consecutive patients after implantation of an ICD or CRT-D manufactured by St.

Jude Medical, Biotronik or Medtronic will undergo an initial evaluation. Patients who have given informed consent and who fulfill the inclusion/exclusion criteria will be screened. Randomization to the RM or control group will be conducted within 30 days after ICD or CRT-D implantation and after the final programming of sensing and stimulation parameters. The time of observation in both groups will be 12 months after randomization. In the RM group only, one follow-up visit will be planned 12 months after being enrolled in the trial. In the control group, follow-up visits will be planned at 3, 6, 9 and 12 months after being enrolled in the trial, according to the normal procedure in our center. Unscheduled visits in both groups can be initiated either by the patient or by the supervising staff. The limits of therapeutic intervention will be individualized depending on the clinical situation according to valid ESC guidelines and will include the following: modification of device settings, modification of pharmacotherapy and performing necessary invasive diagnostic and therapeutic procedures.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heart Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Home Monitoring

Remote monitoring od ICD/CRT-D function and patient condition. Device: HM provided by St Jude Medical, Biotronik or Medtronic.

Group Type EXPERIMENTAL

Home Monitoring

Intervention Type DEVICE

Remote monitoring of ICD/CRT-D function and patient condition allow decreasing costs of treatment of patients with ICD/CRT-D (hospitalization, visits in outpatient clinic) and reducing waiting time for medical intervention (remote or in outpatient clinic).

HM option not active.

Regular visits in outpatient clinic. Device: no HM

Group Type ACTIVE_COMPARATOR

no Home Monitoring

Intervention Type DEVICE

Patients with ICD/CRT-D devices provided by St Jude Medical, Biotronik or Medtronic with HM option switched off.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Home Monitoring

Remote monitoring of ICD/CRT-D function and patient condition allow decreasing costs of treatment of patients with ICD/CRT-D (hospitalization, visits in outpatient clinic) and reducing waiting time for medical intervention (remote or in outpatient clinic).

Intervention Type DEVICE

no Home Monitoring

Patients with ICD/CRT-D devices provided by St Jude Medical, Biotronik or Medtronic with HM option switched off.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age 18-80 years
2. EF≤35% prior to implantation
3. Period up to 30 days after implantation (ICD/CRT-D) according to ESC guidelines
4. Agreement for telemetric supervision
5. Informed consent for clinical trial.

Exclusion Criteria

1. Existence of factors that may cause risk for lack of cooperation in trial regimen (distant residence, mental illness, lack of skills in operating simple electronic devices).
2. unavailability of mobile network service in the place of residence/stay.
3. Device implanted during intravenous administration of inotropic agents.

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No